Logo

Mycovia Reports P-III (ultraVIOLET) Study Results of Vivjoa (oteseconazole) for Recurrent Vulvovaginal Candidiasis

Share this

Mycovia Reports P-III (ultraVIOLET) Study Results of Vivjoa (oteseconazole) for Recurrent Vulvovaginal Candidiasis

Shots:

  • The P-III (ultraVIOLET) study evaluating Vivjoa vs fluconazole in a ratio (2:1) to prevent acute VVC episodes in 219 women with RVVC at 38 US sites. 185 patients who had recovered from acute VVC inf. started the maintenance phase after 2wk. induction phase & received Vivjoa (150mg) for 11wks.
  • The results showed that Vivjoa was superior to PBO for RVVC @50wks. and noninferior to fluconazole for acute VVC in women with RVVC, 94.9% vs 57.8% did not have a VVC episode in the induction phase, followed by PBO in the maintenance phase. The results were published in AJOG
  • In the ITT population, 93.2% vs 95.8% had a resolved VVC episode by Day 14. In the modified ITT population, patients cleared their initial VVC episode by Day 14 (98.5% vs 94.1%), TEAEs (54% vs 64%)

Ref: Businesswire | Image: Mycovia

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions